INTERIM REPORT JANUARY-SEPTEMBER 2013 CHRONTECH PHARMA

· Research and development costs amounted to SEK 1.7 (10.7) m · Profit/loss after tax was SEK 9.1 (-14.9) m · Earnings per share were SEK 0.06 (-0.08) · Net sales SEK 15.1 (-) m · ChronTech has closed the deal concerning the sale of its hepatitis B and C technologies to the Irish company Avac Pharma Ltd. This means that ChronTech has received 625,000 USD, that the earlier loan of 625,000 USD has been assigned to Avac Pharma Ltd, another 1 million USD will be paid on or before the first anniversary of Closing. This payment amount to a total of 15.1 MSEK. Avac Pharma Ltd will furthermore pay up to 1.5 million USD for the further development of ChronTech’s injection technology IVIN. · The Swedish Companies Registration Office has during the period registered the redemption of 80,274,295 shares in ChronTech Pharma AB. · ChronTech has carried out rights offering of shares and convertibles raising approx. 9 MSEK before transaction costs. Both offerings were oversubscribed. As of September 30, 2013 4.7 MSEK has been paid in and the rest has been paid in October 2013. · ChronTech has applied for patent application for a new type of treatment of hepatitis D (HDV). · ChronTech´s IVIN technology allows for lower vaccine doses with maintained efficacy. For more information, please contact: Anders Vahlne, CEO and Head of Research, ChronTech Pharma AB Mobile phone: +46 709 28 05 28 E-mail: anders.vahlne@chrontech.se About ChronTech ChronTech has developed and further develops a patent pending new type of injection needle for a more effective uptake of genetic vaccines (IVIN) and vaccine and therapy for hepatitis D. ChronTech also have part ownership in the new platform technology RAS®. The ChronTech share is admitted to trade on First North. Remium Nordic AB is Certified Adviser for ChronTech. For more information, please visit: www.chrontech.se In the event of any discrepancy between the Swedish and English versions of this press release, the Swedish version will take precedence.